Skip to main content

Stock fraud class actions

Amgen v. Connecticut Retirement Plans and Trust Funds

Updated Oct 19, 2026

In brief

The investors could sue together without first proving Amgen’s alleged statements were important to investors, and the Supreme Court agreed with the Ninth Circuit.

Where it stands
Decided

Decided 6-3 · February 27, 2013 · Opinion by Justice Ginsburg

What it’s about
Connecticut Retirement Plans & Trust Funds brought a securities-fraud class action against Amgen, which argued that investors had to prove the alleged misstatements were important to investors before the case could proceed as a group.
Who it affects
For damages class actions alleging violations of Section 10(b) and Rule 10b-5, courts need not require proof that alleged statements mattered to investors before allowing the group to proceed.

Summary: written with AI from the case record.

Illustration for Amgen Inc. v. Connecticut Retirement Plans and Trust Funds
Conceptual illustration · AI-generated

What it's about

The Supreme Court agreed with the Ninth Circuit that such proof was not required and affirmed its ruling.

Connecticut Retirement Plans & Trust Funds brought a securities-fraud lawsuit against Amgen. Amgen argued that investors first had to show its alleged statements were important to investors before they could sue together.

The case addressed when investors can bring claims together, not whether Amgen ultimately committed securities fraud.

Question presented

Must the district court require proof of materiality before certifying a class action based on the fraud-upon-the-market theory in a misrepresentation case?

What the Court decided

Holding

Proof of materiality is not a prerequisite to certification of a secu-rities-fraud class action seeking money damages for alleged violations of §10(b) and Rule 10b–5. 660 F. 3d 1170, affirmed.

Result
Affirmed

The Court's reasoning

The Court said whether the alleged statements were important to investors is a question for resolving the fraud claims, not a requirement for allowing investors to sue as a group.

The vote

  • Joined the judgment
  • Dissented
  • Wrote an opinion
Majority · 6joined the Court's opinion
  1. Breyer
  2. Kagan
  3. Ginsburgwrote the opinion
  4. Sotomayor
  5. Roberts
  6. Alitoalso wrote separately
Dissenting · 3disagreed with the result
  1. Thomaswrote a dissent
  2. Scaliawrote a dissent
  3. Kennedy
6 justices joined the judgment, 3 dissented.

From the opinions

“Today’s Court applies to that rule the principles of Federal Rule of Civil Procedure 23(b)(3), and thereby concludes (logically enough) that commonality is established at the certification stage even when materiality has not been shown.”

— Justice Scalia(dissent)

What's next

The lawsuit proceeds on the underlying fraud claims. Whether the alleged statements were important to investors remains to be decided when those claims are resolved.

Documents

2

Opinions

  • Amgen

    Ginsburg, Roberts, Breyer, Alito, Sotomayor, Kagan, Abito, Scalia, Thomas, Kennedy, I-B

Audio

View the full docket on supremecourt.gov

Docket activity

10
  • New analysis added

    Oct 19, 2026 · Court records

  • AI analysis generated: Case Briefing

    Oct 19, 2026 · Generated

  • New analysis added

    Oct 19, 2026 · Court records

  • AI analysis generated: Impact Analysis

    Oct 19, 2026 · Generated

  • AI analysis generated: Opinion Summary

    Oct 19, 2026 · Generated

Show 5 more
  • AI analysis generated: Decision Record

    Oct 19, 2026 · Generated

  • Case data updated: summary, question_presented, generation_metadata

    Oct 19, 2026 · Court records

  • Case data updated: question_presented, extraction_metadata

    Oct 17, 2026 · Court records

  • Audio Recording added: Oral Arguments - Amgen Inc. v. Connecticut Retirement Plans and Trust Funds

    Oct 30, 2014 · Court records

  • Opinion added: Amgen

    Feb 27, 2013 · Court records

More questions

1
Did the Court revisit the market-reliance presumption (the rule that market purchases can show investor reliance)?
No. Justice Alito said Amgen had not asked the Court to revisit that rule, though he said reconsideration might be appropriate.

Sources

Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.

Checked Oct 19, 2026Methodology

Court records and filings

Reporting and analysis